AU2021255043B9 - MIV-818/lenvatinib combination therapy for liver cancer - Google Patents

MIV-818/lenvatinib combination therapy for liver cancer Download PDF

Info

Publication number
AU2021255043B9
AU2021255043B9 AU2021255043A AU2021255043A AU2021255043B9 AU 2021255043 B9 AU2021255043 B9 AU 2021255043B9 AU 2021255043 A AU2021255043 A AU 2021255043A AU 2021255043 A AU2021255043 A AU 2021255043A AU 2021255043 B9 AU2021255043 B9 AU 2021255043B9
Authority
AU
Australia
Prior art keywords
miv
compound
lenvatinib
pharmaceutically
liver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021255043A
Other languages
English (en)
Other versions
AU2021255043B2 (en
AU2021255043A1 (en
Inventor
Fredrik ÖBERG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medivir AB
Original Assignee
Medivir AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivir AB filed Critical Medivir AB
Publication of AU2021255043A1 publication Critical patent/AU2021255043A1/en
Publication of AU2021255043B2 publication Critical patent/AU2021255043B2/en
Application granted granted Critical
Publication of AU2021255043B9 publication Critical patent/AU2021255043B9/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Surgical Instruments (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2021255043A 2020-04-15 2021-04-14 MIV-818/lenvatinib combination therapy for liver cancer Active AU2021255043B9 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE2050430-4 2020-04-15
SE2050430 2020-04-15
PCT/SE2021/050338 WO2021211039A1 (en) 2020-04-15 2021-04-14 Miv-818/lenvatinib combination therapy for liver cancer

Publications (3)

Publication Number Publication Date
AU2021255043A1 AU2021255043A1 (en) 2022-11-03
AU2021255043B2 AU2021255043B2 (en) 2025-06-05
AU2021255043B9 true AU2021255043B9 (en) 2025-07-10

Family

ID=78084457

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021255043A Active AU2021255043B9 (en) 2020-04-15 2021-04-14 MIV-818/lenvatinib combination therapy for liver cancer

Country Status (13)

Country Link
US (1) US20240024342A1 (https=)
EP (1) EP4135849B1 (https=)
JP (1) JP7709456B2 (https=)
KR (1) KR20230003522A (https=)
CN (1) CN115485029A (https=)
AU (1) AU2021255043B9 (https=)
CA (1) CA3174940A1 (https=)
ES (1) ES3027841T3 (https=)
HR (1) HRP20250669T1 (https=)
HU (1) HUE071473T2 (https=)
PL (1) PL4135849T3 (https=)
TW (1) TW202200140A (https=)
WO (1) WO2021211039A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113453685A (zh) * 2019-02-18 2021-09-28 美迪维尔公司 使用口服给药的二氧戊环核苷酸与抗pd1或抗pdl1单克隆抗体的组合治疗肝癌的方法
TW202444368A (zh) * 2023-03-30 2024-11-16 瑞典商米迪維艾克提伯拉公司 以氟曲沙他濱布洛帕胺(fostroxacitabine bralpamide)、免疫檢查點抑制劑及vegf拮抗劑治療肝癌之方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017151044A1 (en) * 2016-03-02 2017-09-08 Medivir Ab Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ729118A (en) * 2014-08-25 2022-02-25 Medivir Ab Dioxolane analogues of uridine for the treatment of cancer
RU2019134940A (ru) * 2017-05-16 2021-06-16 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Лечение гепатоцеллюлярной карциномы
CN113453685A (zh) * 2019-02-18 2021-09-28 美迪维尔公司 使用口服给药的二氧戊环核苷酸与抗pd1或抗pdl1单克隆抗体的组合治疗肝癌的方法
US11098002B2 (en) * 2019-07-26 2021-08-24 Espervita Therapeutics, Inc. Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017151044A1 (en) * 2016-03-02 2017-09-08 Medivir Ab Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BETHELL RICHARD, POSTER PRESETATION, THE INTERNATIONAL LIVER CONGRESS, 19 April 2017 (2017-04-19), XP055864782 <URL:https://www.medivir.com/media/1196/liver-targeting-with-the-novel-nucleotide-prodrug-miv-818.pdf> *
BILJANA RIZOSKA et al. EXPERIMENTAL AND MOLECULAR THERAPEUTICS, AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1 July 2018 (2018-07-01), pages 2930 - 2930, XP055624767, DOI: 10.1158/1538-7445.AM2018-2930 *
KIM, J.J. et al. The Oncologist (2019) Vol.25, pages e512 to e519, DOI:10.1634/theoncologist.2019-0501 *
RICHARD BETHELL et al. HEPATOLOGY INTERNATIONAL, vol. 11, no. Suppl. 1, 15 February 2017 (2017-02-15), pages S67, XP009531587 *

Also Published As

Publication number Publication date
HRP20250669T1 (hr) 2025-08-01
EP4135849A1 (en) 2023-02-22
JP2023522325A (ja) 2023-05-30
US20240024342A1 (en) 2024-01-25
EP4135849B1 (en) 2025-03-19
EP4135849A4 (en) 2024-04-17
WO2021211039A1 (en) 2021-10-21
ES3027841T3 (en) 2025-06-17
AU2021255043B2 (en) 2025-06-05
KR20230003522A (ko) 2023-01-06
HUE071473T2 (hu) 2025-09-28
PL4135849T3 (pl) 2025-07-14
CN115485029A (zh) 2022-12-16
JP7709456B2 (ja) 2025-07-16
AU2021255043A1 (en) 2022-11-03
EP4135849C0 (en) 2025-03-19
CA3174940A1 (en) 2021-10-21
TW202200140A (zh) 2022-01-01

Similar Documents

Publication Publication Date Title
AU2022203761B2 (en) Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine
Herreros-Villanueva et al. Adjuvant and neoadjuvant treatment in pancreatic cancer
WO2017037292A1 (en) Combination of a dhodh inhibitor and a her inhibitor for use in the treatment of cancer
AU2021255043B9 (en) MIV-818/lenvatinib combination therapy for liver cancer
ES2391841T3 (es) Combinación antiproliferativa que comprende CYC-682 y un agente citotóxico
JP2022532189A (ja) 軟部肉腫の併用療法用キノリン誘導体
HK40081068A (en) Miv-818/lenvatinib combination therapy for liver cancer
HK40040637B (zh) 索拉非尼或瑞戈非尼与曲沙他滨的氨基磷酸酯前药的组合治疗
HK40040637A (en) Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine
BR112018067387B1 (pt) Uso de um agente terapêutico
HK40000353A (en) Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine
HK40000353B (en) Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine
Khan et al. b. Systemic therapy
JP2014091711A (ja) Ｈｓｐ９０阻害剤と抗腫瘍性白金錯体との組み合わせ

Legal Events

Date Code Title Description
SREP Specification republished
FGA Letters patent sealed or granted (standard patent)